Journal
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
Volume 81, Issue 4, Pages 272-275Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/00365513.2021.1926536
Keywords
renin-angiotensin-aldosterone system; angiotensin; ACE; COVID-19
Categories
Funding
- University of Cincinnati College of Medicine Special Coronavirus (COVID-19) Research Pilot Grant Program
- NIH Pediatric Center of Excellence in Nephrology [P50DK096418]
Ask authors/readers for more resources
This study examined plasma ACE concentration and serum ACE activity in COVID-19 patients and non-COVID-19 sick controls, finding no significant differences between the two groups. Additionally, ACE activity and concentration were not associated with the severity of COVID-19 or inflammatory biomarkers.
Significant controversy has arisen over the role of the renin-angiotensin-aldosterone system (RAAS) in COVID-19 pathophysiology. In this prospective, observational study, we evaluated plasma angiotensin converting enzyme (ACE) concentration and serum ACE activity in 52 adults with laboratory-confirmed SARS-CoV-2 infection and 27 non-COVID-19 sick controls. No significant differences were observed in ACE activity in COVID-19 patients versus non-COVID-19 sick controls (41.1 [interquartile range (IQR): 23.0-55.2] vs. 42.9 [IQR 13.6-74.2] U/L, p = .649, respectively). Similarly, no differences were observed in ACE concentration in COVID-19 patients versus non-COVID-19 sick controls (108.4 [IQR: 95.8-142.2] vs. 133.8 [IQR: 100.2-173.7] mu g/L, p = .059, respectively). Neither ACE activity (p = .751), nor ACE concentration (p = .283) was associated with COVID-19 severity. Moreover, neither ACE activity, nor ACE concentration was correlated with any inflammatory biomarkers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available